03.01.13
After increasing its cash offer to purchase Norwegian fish oil manufacturer Pronova BioPharma, BASF has secured more than 97% acceptance from shareholders. Based on all outstanding shares and including all net financial liabilities, the enterprise value would be approximately €684 million. All regulatory approvals required for completion of the offer have been obtained.
With the acquisition of Pronova, BASF will achieve a leading position in the global market for omega 3 fatty acids. Pronova will become a key part of BASF’s omega 3 business. Pronova’s active pharmaceutical ingredients are used to treat cardiovascular diseases such as post-myocardial infarction. In nutritional applications, including dietary supplements, there is a strong body of evidence supporting a broad range of positive health benefits through omega 3 fatty acids, for example, in the areas of cognitive development and heart health.
With the acquisition of Pronova, BASF will achieve a leading position in the global market for omega 3 fatty acids. Pronova will become a key part of BASF’s omega 3 business. Pronova’s active pharmaceutical ingredients are used to treat cardiovascular diseases such as post-myocardial infarction. In nutritional applications, including dietary supplements, there is a strong body of evidence supporting a broad range of positive health benefits through omega 3 fatty acids, for example, in the areas of cognitive development and heart health.